Menu
Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 11-20 of 59
Pediatric Blood Cancer
AML23: A Phase 2 study of venetoclax in children with newly diagnosed AML
AML23: A Phase 2 study of venetoclax in children with newly diagnosed AML Summary: Although the survival rates for children with acute myeloid leukemia (AML) have reached 70%, little improvement has been made in the past 20 years. Approximately 25% of patients relapse and only about 40% of these patients are subsequently cured. It is highly unlikely that improvements can be made […]
Hiroto Inaba, MD, PhD
St. Jude Children's Research Hospital
Solid Tumors
Psilocybin-Assisted Psychotherapy in Patients with Advanced Cancer on Maintenance Therapy Experiencing Depression and/or Anxiety
Psilocybin-Assisted Psychotherapy in Patients with Advanced Cancer on Maintenance Therapy Experiencing Depression and/or Anxiety Summary: Advances in systemic treatments like immunotherapy and targeted therapies have changed the way we think about cancer. A cancer diagnosis is no longer just a question of cure or death; there is a third possibility of living with cancer as […]
Moran Amit, MD, PhD
MD Anderson Cancer Center
Lung Cancer
Personalized Neoantigen Vaccine and Durvalumab in ES-SCLC
Personalized Neoantigen Vaccine and Durvalumab in ES-SCLC Summary: Small cell lung cancer (SCLC) is an aggressive type of lung cancer that accounts for up to 15% of all new diagnoses of lung cancers. Each year, over 30,000 new patients will be diagnosed with SCLC in the United States. Treatment for patients with extensive stage SCLC, […]
Jeffrey Ward, MD, PhD
Washington University in St. Louis
Kidney Cancer
Phase II Trial of Relatlimab plus Nivolumab in Renal Medullary Carcinoma
Clinical TrialPhase II Trial of Relatlimab plus Nivolumab in Renal Medullary Carcinoma Summary: Renal medullary carcinoma (RMC) is a rare kidney cancer that predominately affects those of African descent carrying the sickle cell trait. Additionally, it is one of the most aggressive kidney cancers with approximately 67% of patients presenting with metastatic disease at diagnosis […]
Pavlos Msaouel, MD PhD
MD Anderson Cancer Center
Solid Tumors
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With Brain metastasis of TNBC, NSCLC, and Other Tumor Types
Clinical TrialPhase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With Brain metastasis of TNBC, NSCLC, and Other Tumor Types Summary: Approximately 200,00 patients are diagnosed with brain metastasis in the United States annually, comprising about 10% of all cancer patients. Furthermore, approximately 100,000 patients die from brain metastasis each year, meaning that […]
Jordi Rodon, MD, PhD
MD Anderson Cancer Center
All Cancers
Pan-cancer telemedicine registry of immunotherapy responses in patients with structural variations in PD-1 ligands
Pan-cancer telemedicine registry of immunotherapy responses in patients with structural variations in PD-1 ligands Summary: Cancer cells evolve and develop protective mechanisms to hide themselves from cancer killing T-cells. Immune checkpoint inhibitors (ICIs), block these protective mechanisms by targeting PD-1/PD-L1, unhiding cancer cells so that they can be killed by T-cells. Immune checkpoint inhibitors have […]
Sameek Roychowdhury, MD, PhD
The Ohio State University
Breast Cancer
Acupuncture for Preventing Progression of Chemotherapy-Induced Peripheral Neuropathy (ACP)
Acupuncture for Preventing Progression of Chemotherapy-Induced Peripheral Neuropathy (ACP) Summary: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and severe toxicities caused by certain chemotherapies affecting 30-40% of breast cancer patients. CIPN symptoms include pain, tingling, and numbness which can increase the risk of falls and decrease quality of life. As a result of CIPN, […]
Wanqing Iris Zhi, MD, PhD
Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Wild-type IDH1 inhibition as a novel treatment for pancreatic cancer
Wild-type IDH1 inhibition as a novel treatment for pancreatic cancer Summary: Pancreatic cancer is the twelfth most common cancer but is the third leading cause of cancer death in the United States. The 5-year survival is just 3% for those with metastatic disease and 34% with localized disease, the worst of the common cancers. Currently, […]
Jordan Winters, MD
University Hospitals Cleveland Medical Center
Breast Cancer
The STOP-HER2 Study
The STOP-HER2 Study Summary: HER2 positive (HER2+) breast cancers account for 20-25% of breast cancers and are associated with higher rates of recurrence and brain metastases. However, in the past two decades, HER2 targeting therapies have drastically improved patient outcomes and most patients treated with stage I-III HER2+ breast cancer are cured. For patients with […]
Heather Parsons, MD, MPH
Dana-Farber Cancer Institute
Colorectal Cancer
SX-682 in combination with Nivolumab for ctDNA positive colorectal cancer
SX-682 in combination with Nivolumab for ctDNA positive colorectal cancer Summary: STOPTRAFFIC-1 is an ongoing phase I/II study assessing the experimental drug, SX-682, in patients with refractory RAS-mutated microsatellite stable (MSS) metastatic colorectal cancer. In collaboration with the NCI/SPORE program, Gateway will support the proposed “Arm B” of the study. This arm will assess colorectal […]
Alisha Bent, MD
MD Anderson Cancer Center
